Recent Global Patterns in Prostate Cancer Incidence and Mortality Rates

Published on Jan 1, 2020in European Urology17.298
· DOI :10.1016/j.eururo.2019.08.005
MaryBeth B. Culp1
Estimated H-index: 1
(ACS: American Cancer Society),
Isabelle Soerjomataram41
Estimated H-index: 41
(IARC: International Agency for Research on Cancer)
+ 2 AuthorsAhmedin Jemal106
Estimated H-index: 106
(ACS: American Cancer Society)
Abstract Context Previous studies have reported significant variation in prostate cancer rates and trends mainly due to differences in detection practices, availability of treatment, and underlying genetic susceptibility. Objective To assess recent worldwide prostate cancer incidence, mortality rates, and trends using up-to-date incidence and mortality data. Evidence acquisition We present estimated age-standardized prostate cancer incidence and mortality rates by country and world regions for 2018 based on the GLOBOCAN database. We also examined rates and temporal trends for incidence (44 countries) and mortality (76 countries) based on data series from population-based registries. Evidence synthesis The highest estimated incidence rates were found in Australia/New Zealand, Northern America, Western and Northern Europe, and the Caribbean, and the lowest rates were found in South-Central Asia, Northern Africa, and South-Eastern and Eastern Asia. The highest estimated mortality rates were found in the Caribbean (Barbados, Trinidad and Tobago, and Cuba), sub-Saharan Africa (South Africa), parts of former Soviet Union (Lithuania, Estonia, and Latvia), whereas the lowest rates were found in Asia (Thailand and Turkmenistan). Prostate cancer incidence rates during the most recent 5 yr declined (five countries) or stabilized (35 countries), after increasing for many years; in contrast, rates continued to increase for four countries in Eastern Europe and Asia. During the most recent 5 data years, mortality rates among the 76 countries examined increased (three countries), remained stable (59 countries), or decreased (14 countries). Conclusions As evident from available data, prostate cancer incidence and mortality rates have been on the decline or have stabilized recently in many countries, with decreases more pronounced in high-income countries. These trends may reflect a decline in prostate-specific antigen testing (incidence) and improvements in treatment (mortality). Patient summary We examined recent trends in prostate cancer incidence and mortality rates in 44 and 76 countries, respectively, and found that rates in most countries stabilized or decreased.
  • References (37)
  • Citations (4)
📖 Papers frequently viewed together
845 Citations
147 Citations
78% of Scinapse members use related papers. After signing in, all features are FREE.
#1Laurie TononH-Index: 6
#2Gaëlle FromontH-Index: 29
Last. Olivier Cussenot (University of Paris)H-Index: 55
view all 19 authors...
Causes of high mortality of prostate cancer in men of African ancestry living in the French West Indies are still debated, between suspicions of environmental factors and genetic susceptibility. We report an integrated genomic study of 25 tumour tissues from radical prostatectomy of aggressive (defined by International Society of Urological Pathology !3) prostate cancer patients (10 African Caribbean and 15 French Caucasian) using single nucleotide polymorphism arrays, whole-genome sequencing, a...
6 CitationsSource
#1Kari A.O. Tikkinen (UH: University of Helsinki)H-Index: 23
#2Philipp Dahm (UMN: University of Minnesota)H-Index: 41
Last. Thomas Agoritsas (McMaster University)H-Index: 28
view all 19 authors...
### What you need to know What is the role of prostate-specific antigen (PSA) screening in prostate cancer? An expert panel produced these recommendations based on a linked systematic review.1 The review was triggered by a large scale, cluster randomised trial on PSA screening in men without a previous diagnosis of prostate cancer published in 2018 (box 1).2 It found no difference between one-time PSA screening and standard practice in prostate cancer mortality but found an increase in the detec...
8 CitationsSource
#1Wayne A. Warner (WashU: Washington University in St. Louis)H-Index: 3
#2Tammy Y. Lee (California State University, Los Angeles)H-Index: 2
Last. Adana A.M. Llanos (RU: Rutgers University)H-Index: 11
view all 17 authors...
Cancer is the second leading cause of death in the Caribbean, including the islands of Trinidad and Tobago (TT). The population of TT consists of over 1.3 million people with diverse ancestral and sociocultural backgrounds, both of which may influence cancer incidence and mortality. The objective of this study was to examine incidence and mortality patterns and trends in TT. Cancer surveillance data on 29,512 incident cancer cases reported to the Dr. Elizabeth Quamina Cancer Registry (population...
2 CitationsSource
#1James T. Kearns (UW: University of Washington)H-Index: 4
#2Sarah K. Holt (UW: University of Washington)H-Index: 22
Last. John L. Gore (UW: University of Washington)H-Index: 35
view all 6 authors...
8 CitationsSource
#1Serban NegoitaH-Index: 3
#2Eric J. FeuerH-Index: 61
Last. Lynne PenberthyH-Index: 30
view all 18 authors...
30 CitationsSource
#1David C. Grossman (KP: Kaiser Permanente)H-Index: 19
#2Susan J. Curry (UI: University of Iowa)H-Index: 27
Last. Chien Wen Tseng (UH: University of Hawaii)H-Index: 25
view all 18 authors...
Importance In the United States, the lifetime risk of being diagnosed with prostate cancer is approximately 11%, and the lifetime risk of dying of prostate cancer is 2.5%. The median age of death from prostate cancer is 80 years. Many men with prostate cancer never experience symptoms and, without screening, would never know they have the disease. African American men and men with a family history of prostate cancer have an increased risk of prostate cancer compared with other men. Objective To ...
184 CitationsSource
#1Richard M. Martin (UoB: University of Bristol)H-Index: 102
#2Jenny L Donovan (NIHR: National Institute for Health Research)H-Index: 82
Last. Freddie C. Hamdy (University of Oxford)H-Index: 71
view all 26 authors...
Importance Prostate cancer screening remains controversial because potential mortality or quality-of-life benefits may be outweighed by harms from overdetection and overtreatment. Objective To evaluate the effect of a single prostate-specific antigen (PSA) screening intervention and standardized diagnostic pathway on prostate cancer–specific mortality. Design, Setting, and Participants The Cluster Randomized Trial of PSA Testing for Prostate Cancer (CAP) included 419 582 men aged 50 to 69 years ...
63 CitationsSource
#2Sean C. Skeldon (U of T: University of Toronto)H-Index: 6
Last. S. Larry Goldenberg (UBC: University of British Columbia)H-Index: 41
view all 9 authors...
Introduction: In 2014, the Canadian Task Force on Preventive Health Care (CTFPHC) recommended against routine prostate cancer screening with the prostate-specific antigen (PSA) blood test.1 We surveyed Canadian primary care physicians (PCPs) to understand their opinions and attitudes towards prostate cancer screening in 2016. Methods: Twenty PCPs piloted the survey to assess its accessibility. We distributed a flyer to 19 633 PCPs as an insert in a large mailed package inviting them to attend a ...
2 CitationsSource
#1Stacey A. Fedewa (ACS: American Cancer Society)H-Index: 34
#2Elizabeth Ward (ACS: American Cancer Society)H-Index: 72
Last. Ahmedin Jemal (ACS: American Cancer Society)H-Index: 106
view all 4 authors...
12 CitationsSource
#1Renu S. EapenH-Index: 4
#2Annika HerlemannH-Index: 7
Last. Matthew R. CooperbergH-Index: 55
view all 4 authors...
Purpose of review In 2012, the United States Preventive Services Task Force (USPSTF) issued a grade 'D' recommendation against the use of routine prostate-specific antigen (PSA)-based screening for any men. This recommendation reflects critical misinterpretations of the available evidence base regarding benefits and harms of PSA screening and has influenced the nationwide landscape of prostate cancer screening, diagnosis, and treatment. Recent findings Following the USPSTF recommendation, a subs...
19 CitationsSource
Cited By4
#1Lin Bai (PKU: Peking University)
#2Haishaerjiang Wushouer (PKU: Peking University)H-Index: 2
Last. Luwen Shi (PKU: Peking University)H-Index: 5
view all 6 authors...
Background: Prostate cancer is one of the highest increasing cancers in medical costs with tremendous economic burden, but the evidence on health care utilization and medical expenditure of prostate cancer was absent in China. Objective: This study aimed to analyze health care utilization and direct medical costs of patients with prostate cancer in China. Methods: Health care service data with a national representative sample of basic medical insurance beneficiaries between 2015 and 2017 were ob...
#1Amir H. LebastchiH-Index: 2
#2Arvin K. George (UM: University of Michigan)H-Index: 26
Last. Sangeet Ghai (Women's College Hospital)H-Index: 16
view all 21 authors...
Abstract Background Focal therapy (FT) and partial gland ablation (PGA) are quickly adopted by urologists and radiologists as an option for the management of localized prostate cancer. Objective To find consensus on a standardized nomenclature and to define a follow-up guideline after FT and PGA for localized prostate cancer in clinical practice. Design, setting, and participants A review of the literature identified controversial topics in the field of FT. Online questionnaires were distributed...
#1Masaki MomotaH-Index: 3
#2Shingo Hatakeyama (Hirosaki University)H-Index: 23
Last. Atsushi ImaiH-Index: 12
view all 14 authors...
OBJECTIVES To evaluate the association between the score of the Geriatric 8 screening tool and treatment by disease stages in patients with prostate cancer. METHODS Between January 2017 and June 2019, we prospectively evaluated the Geriatric 8 in 540 prostate cancer patients who were treated with robot-assisted radical prostatectomy, radiotherapy, androgen deprivation therapy alone and standard of care for metastatic hormone-naive prostate cancer or castration-resistant prostate cancer. The prim...
1 CitationsSource
#1Shuang Liu (MUC: Minzu University of China)
Last. Yaojiang Huang (Harvard University)
view all 5 authors...
Background: Prostate cancer (PCa)is a malignancy of the urinary system with a high incidence, which is the second most common male cancer in the world. There are still huge challenges in the treatment of prostate cancer. It is urgent to screen out potential key biomarkers for the pathogenesis and prognosis of PCa. Methods: Multiple gene differential expression profile datasets of PCa tissues and normal prostate tissues were integrated analysis by R software. Gene Ontology (GO) and Kyoto Encyclop...
#1A. Bertolet (HUP: Hospital of the University of Pennsylvania)
#2A. Carabe-Fernandez (HUP: Hospital of the University of Pennsylvania)
Purpose: To study the potential consequences of differences in the evaluation of variable versus uniform relative biological effectiveness calculations in proton radiotherapy for prostate cancer.Me...
#1Marius KinciusH-Index: 5
#2Ausvydas Patasius (Vilnius University)
Last. Giedre Smailyte (Vilnius University)H-Index: 11
view all 5 authors...
: Background: During the past decade, a huge interest was devoted to the type-2 diabetes mellitus and their associations with prostate cancer development.Objectives: The aim of this study was to determine whether type 2 diabetes mellitus and treatment with metformin is associated with prostate cancer risk.Materials and methods: The cohort was composed of diabetic male patients identified in the National Health Insurance Fund database during 2000-2016 and cancer cases in national Cancer Registry....
#1Masaki Momota (Hirosaki University)H-Index: 3
#2Shingo Hatakeyama (Hirosaki University)H-Index: 23
Last. Hayato Yamamoto (Hirosaki University)H-Index: 14
view all 13 authors...
Brazilian red propolis has been proposed as a new source of compounds with cytotoxic activity. Red propolis is a resinous material of vegetal origin, synthesized from the bees of the Appis mellifera family, with recognized biological properties. To obtain actives of low polarity and high cytotoxic profile from red propolis, in this work, we proposed a new solvent accelerated extraction method. A complete 23 factorial design was carried out to evaluate the influence of the independent variables o...
#1Greta Carioli (University of Milan)H-Index: 11
#2Paola Bertuccio (University of Milan)H-Index: 38
Last. Matteo Malvezzi (University of Milan)H-Index: 31
view all 7 authors...
Background Current cancer mortality figures are important for disease management and resource allocation. We estimated mortality counts and rates for 2020 in the European Union (EU) and for its six most populous countries. Materials and methods We obtained cancer death certification and population data from the World Health Organization and Eurostat databases for 1970–2015. We estimated projections to 2020 for 10 major cancer sites plus all neoplasms and calculated the number of avoided deaths o...
#1Ausvydas Patasius (Vilnius University)
#2Giedre Smailyte (Vilnius University)H-Index: 11